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Introduction
Allogeneic hematopoietic stem cell transplantation (alloSCT) is 
the most successful and widely applied form of adoptive T cell 
immunotherapy. Alloreactive αβ T cells in allografts can rec-
ognize and kill recipient leukemia cells, thereby mediating the 
graft-versus-leukemia (GVL) effect (1). Unfortunately, alloreac-
tive T cells also attack nonmalignant host tissues, causing graft-
versus-host disease (GVHD) (2–4). A longstanding and elusive 
objective has been to develop approaches that preserve GVL 
while minimizing GVHD. A second and arguably more import-
ant goal is to overcome GVL resistance, as relapse of malignant 
neoplasms is the greatest single cause of post-transplantation 
mortality (5). GVL resistance and sensitivity are not equal across 
different types of hematopoietic malignancies. For example, 
chronic phase chronic myelogenous leukemia (CP-CML) is 
exquisitely GVL sensitive, whereas blast crisis CML (BC-CML) 
is relatively GVL resistant, despite the two sharing a common 
biology, in that both are reliant on breakpoint cluster region/
Abelson murine leukemia viral oncogene homolog 1 (BCR/ABL) 
signaling (6–8). Acute myeloid leukemias (AML) and acute lym-
phoblastic leukemias are also relatively GVL resistant.
Because GVL resistance and  sensitivity track with the 
identity of the underlying neoplasm, we reasoned that they are 
leukemia cell–intrinsic properties. To understand the mech-
anisms of GVL resistance, we used mouse models to evaluate 
GVL against CP-CML (mCP-CML) and BC-CML (mBC-CML) 
(9–11). mCP-CML is created via retroviral transfer of the 
BCR-ABL fusion cDNA, the defining genetic abnormality of 
CP-CML, into mouse BM cells (12, 13), whereas mBC-CML is 
created via retroviral transfer of both BCR-ABL and nucleoporin 
98–homeobox A9 (NUP98-HOXA9) fusion cDNAs (14, 15). The 
NUP98-HOXA9 fusion is a second-hit translocation in BC-CML 
that has also been identified in de novo AML (14–22), as have 
NUP98 fusions with other class I HOX genes. mCP-CML and 
mBC-CML are therefore excellent phenocopies and genocopies 
of their human counterparts, have defined stem cell populations 
(15, 23), and, importantly, are GVL sensitive and GVL resis-
tant, respectively (11). A powerful advantage of this approach 
is that, by transducing BM from gene-deficient mice, we can 
create gene-deficient leukemias as a means to explore mecha-
nisms of GVL resistance (10, 11, 24–26). Using these systems, 
we found that GVL against mCP-CML and GVL against mBC-
CML share essential features: (a) both leukemias must express 
ICAM1; (b) T cell killing mechanisms are highly redundant; 
and (c) CD8+ and CD4+ T cell killing requires T cell receptor– 
MHCI (TCR-MHCI) or TCR-MHCII interactions, respectively 
(11, 24, 25). Paradoxically, however, despite the fact that 
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Results
MHCII and MHCI are upregulated on leukemia cells in a GVH envi-
ronment. Although MHCII-/- mCP-CML and mBC-CML were 
completely resistant to CD4-mediated GVL, staining for surface 
MHCII on WT and MHCII-/- LSCs harvested from sublethally 
irradiated syngeneic recipients or alloBMT recipients that did not 
receive donor T cells was similar (ref. 11 and Figure 1A). To account 
for the MHCII requirement in GVL, we hypothesized that surface 
MHCII was upregulated in an alloimmune environment. To test 
this, we analyzed mBC-CML and mCP-CML cells from mice with 
or without an ongoing GVH response in the C3H.SW→B6 mod-
el. MHCII was upregulated on both mBC-CML LSCs (lineage– 
[lin–]or CD11b–) (ref. 15 and data not shown) and mCP-CML LSCs 
(lin–sca-1+c-kit+) (ref. 28 and Figure 1B) harvested from mice in 
which GVH was induced by either CD4 or CD8 cells. We found 
that MHCI was consistently upregulated on mBC-CML LSCs but 
minimally and inconsistently so on mCP-CML LSCs (Figure 1B).
MHC upregulation does not require TCR-MHC interactions. 
Because CD4-mediated GVL absolutely requires both mCP-CML 
and mBC-CML to express MHCII (10, 11, 24), we reasoned that 
MHCII upregulation would occur in the GVH environment inde-
MHCII-deficient mCP-CML and mBC-CML were completely 
resistant to CD4-mediated GVL, WT mCP-CML and mBC-
CML leukemia stem cells (LSCs) expressed little to no surface 
MHCII, as MHCII staining was similar in WT and MHCII- 
deficient LSCs (11). Here, we report that expression of MHCII 
and MHCI on mBC-CML and MHCII on mouse AML (mAML; 
induced by transduction with the MLL-AF9 fusion cDNA) (27) 
and mCP-CML LSCs is upregulated in the alloimmune environ-
ment. Upregulation of MHC on mBC-CML and mAML required 
IFN-γ receptor (IFN-γR) stimulation, whereas MHC upregula-
tion on mCP-CML LSCs was entirely independent of IFN-γR or 
IFN-α/β (IFNAR1) signaling. Importantly, IFN-γR–deficient 
(Ifngr–/–) mBC-CML and mAML were highly resistant to both 
CD4- and CD8-mediated GVL, whereas Ifngr–/–, Ifngr–/– Ifnar1–/–, 
and Stat1–/– Stat2–/– mCP-CML were fully GVL sensitive. Our data 
further suggest that IFN-γ sensitizes myeloblastic leukemias to 
GVL by mechanisms beyond simply upregulating MHC. The 
differential requirements for IFN-γ stimulation at least in part 
explain the exquisite GVL sensitivity of CP-CML and GVL resis-
tance of myeloblastic leukemias and suggest a therapeutic strate-
gy for overcoming the GVL resistance of myeloblastic leukemias.
Figure 1. Expression of MHC molecules on mCP-CML 
and mBC-CML LSCs increases in the alloimmune 
environment, independently of cognate TCR-MHC 
interactions. MHCII expression on WT and MHCII–/– 
mBC-CML (A, left) or mCP-CML (A, right) LSCs harvested 
from mice transplanted with leukemia cells but without 
GVH-inducing T cells. (B) Irradiated B6 mice were 
reconstituted with C3H.SW BM and CD4 or CD8 T cells 
and either mBC-CML or mCP-CML. Mice were sacrificed 
between days 10 and 14, and LSCs were analyzed for 
MHCI and MHCII expression. Representative data from 
at least 3 independent experiments are shown. (C) 
Irradiated B6 mice were reconstituted with C3H.SW BM 
with B6 B2m–/– mBC-CML (MHCI–) and C3H.SW CD8 cells; 
B6 MHCII–/– mBC-CML (MHCII–) and C3H.SW CD4 cells; 
or WT B6 mBC-CML and C3H.SW CD4 or CD8 cells. On 
day 15 after BMT, splenocytes were harvested, and MHCI 
and MHCII expression on mBC-CML LSCs was assessed. 
Similar MHC upregulation was noted on LSCs harvested 
from BM (data not shown). Data are representative of 3 
independent experiments. (D) Mice were transplanted 
as in C, except with B2m–/– or MHCII–/– mCP-CML cells. 
MHC upregulation was also independent of TCR-MHC 
interactions. (E) Irradiated BALB/c mice were recon-
stituted with B6 BM and B6 mCP-CML with no T cells 
or with B6 CD4 or CD8 cells. MHCII and MHCI were 
upregulated on splenic mCP-CML LSCs on day 15 after 
BMT. Similar MHC upregulation was seen in BM LSCs 
(data not shown). (F) MHCIIhi and MHCIIlo mBC-CML LSCs 
from mice undergoing a GVHD response (C3H.SW→B6 
model with GVH induced by CD4 cells) were sort purified 
and transferred into sublethally irradiated B6 mice. Both 
populations transferred disease (F, left panels). Progeny 
of sorted MHCIIhi and MHCIIlo mBC-CML cells recovered 
15 days after transfer were MHCIIlo (F, right panel). FMO, 
fluorescence minus one.
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LSCs in GVH mice relative to LSCs in mice that did not receive 
donor T cells (Figure 1E).
MHCIIhi mBC-CML cells can serially transplant leukemia. To 
determine whether LSC-phenotype cells induced to express 
MHCII have functional properties of LSCs, we sort purified 
MHCIIhiCD11b– and MHCIIloCD11b– mBC-CML cells from mice 
undergoing a GVH response and transferred them into sublethally 
irradiated syngeneic B6 mice. Both MHCIIlo and MHCIIhi mBC-
CML cells transferred mBC-CML, but the progeny of MHCIIhi 
cells lost MHCII expression (Figure 1F), indicating that MHCII 
upregulation was transient.
Role of IFNs in leukemia MHC upregulation and GVL. IFNs 
upregulate MHC on many cell types. To test the role of IFNs 
in GVH-induced MHC upregulation on mBC-CML cells, we 
created type I IFN receptor–deficient (Ifnar1–/–) and IFN-γR–
deficient (Ifngr–/–) mBC-CML. Whereas MHC upregulation 
pendently of TCR interactions with MHC on mBC-CML or mCP-
CML LSCs. Consistent with this, donor CD8+ T cells induced 
MHCII upregulation on MHCI-deficient (β-2-microglobulin– 
deficient, referred to herein as B2m–/–) B6 mBC-CML and mCP-
CML, and CD4 cells induced MHCI upregulation on MHCII- 
deficient B6 mBC-CML cells (Figure 1, C and D). To further inves-
tigate the requirement of TCR-MHC interactions for MHC upreg-
ulation, we asked whether donor-strain mCP-CML cells in mice 
undergoing a GVH response would upregulate MHCII. Irradiated 
BALB/c mice were reconstituted with B6 BM and B6 mCP-CML 
cells, with or without B6 CD4 or CD8 cells. In this design, donor 
T cells are activated by host BALB/c cells, but because the T cells 
are syngeneic with the B6 mCP-CML, they do not mediate GVL 
and presumably do not have high-avidity TCR-MHC interactions 
with them. In line with data using MHC-deficient mCP-CML, 
we observed that MHCII was upregulated on donor mCP-CML 
Figure 2. The IFN-γR on 
mBC-CML cells is required for 
GVH-induced MHC upregula-
tion and effective CD4- and 
CD8-mediated GVL, whereas 
MHCII upregulation on mCP-CML 
cells and GVL are independent 
of both the IFN-γR and IFNAR1 
and STAT1/STAT2. (A) Irradiated 
B6 mice were reconstituted with 
C3H.SW BM and B6 Ifngr–/–, B6 
Ifnar1–/–, or control WT B6 mBC-
CML cells, with no C3H.SW T cells 
or C3H.SW CD4 or CD8 cells. MHCI 
and MHCII upregulation did not 
occur on Ifngr–/– mBC-CML LSCs 
but was intact on Ifnar1–/– LSCs. 
(B) Mice were transplanted as in 
A, except with B6 WT or Ifngr–/– 
mCP-CML cells. MHCII upreg-
ulation was similar in WT and 
gene-deficient mCP-CML LSCs. 
Consistent with the upregula-
tion data, IFN-γR mBC-CML was 
resistant to CD4- and CD8-me-
diated GVL in the C3H.SW→B6 
model (C) and to CD8-mediated 
GVL in the BALB/c→B6 model 
(D). In contrast, Ifngr–/– mCP-CML 
(E), Ifnar1–/– mBC-CML (F), Ifngr–/– 
Ifnar1–/– (double-KO [DKO]) mCP-
CML (G), and Stat1–/– Stat2–/–  
mCP-CML  (H) cells were GVL 
sensitive. Experiments shown 
in E–H were in the C3H.SW→B6 
model. AR1, IFNAR1–/–. P < 0.006, 
comparing any WT mBC-CML 
or IFNAR mBC-CML CD4 or CD8 
recipient group with its BM-alone 
control; P < 0.002, comparing 
any mCP-CML T cell recipient 
group with its BM-alone control. 
P values determined by 2-tailed 
Mann-Whitney U test.
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BALB/c (H-2d)→B6 MHC-mismatched system, in which it would 
be unlikely that CD8 alloimmunity would rely on a single miHA. 
Even with an MHCI mismatch, IFN-γR–/– mBC-CML was com-
pletely resistant to CD8-mediated GVL (Figure 2D), suggesting 
that IFN-γ sensitization of mBC-CML cells to CD8-mediated 
GVL involves more than MHCI upregulation.
We also compared the GVL effect against WT and Ifngr–/– 
mBC-CML mediated by memory T cells raised against the miHA 
H60 (26, 29, 30). C3H.SW mice (H60–) were vaccinated against 
H60 as previously reported (26). B6.H60 mice (congenic for H60) 
were irradiated and reconstituted with C3H.SW BM, with WT or 
Ifngr–/– B6.H60 mBC-CML with no T cells, or with 5 × 104 sort- 
purified CD8+CD44+ cells from H60-vaccinated mice (TMH60) 
containing 3,500 H60-reactive cells as determined by H60 
tetramer staining (TetH60; data not shown). Ifngr–/– B6.H60 mBC-
CML was highly GVL resistant (Figure 3A, survival), despite an 
was intact in Ifnar1–/– mBC-CML cells, we found that it was 
completely abrogated in Ifngr–/– mBC-CML cells (Figure 2A). 
In contrast, MHCII upregulation was similar in WT and Ifngr–/– 
mCP-CML LSCs harvested from GVH mice (Figure 2B). Strik-
ingly, consistent with the MHC upregulation data, Ifngr–/– mBC-
CML was completely resistant to CD4- and CD8-mediated 
GVL in the C3H.SW→B6 strain pairing (Figure 2C), whereas 
Ifnar1–/– mBC-CML, Ifngr–/– mCP-CML, Ifngr–/– Ifnar1–/–, and 
Stat1–/– Stat2–/– mCP-CML were as GVL sensitive as their WT 
counterparts (Figure 2, E–H). It was unexpected that Ifngr–/– 
mBC-CML was completely resistant to CD8-mediated GVL as 
there is substantial basal MHCI expression that is only modestly 
increased with IFN-γ stimulation. We considered the possibil-
ity that there is a dominant, targeted minor histocompatibility 
antigen (miHA) that depends on IFN-γ for its generation and 
presentation. We therefore performed a GVL experiment in the 
Figure 3. IFN-γ stimulation is required for 
TMH60-mediated GVL against H60+ mBC-CML 
and CD4- and CD8-mediated GVL against 
MLL-AF9–induced AML. (A–E). Irradiated 
B6.H60 mice were reconstituted with C3H.
SW BM, WT or Ifngr–/– B6.H60 mBC-CML, 
with no T cells or with and 5 × 104 sort-puri-
fied CD8+CD44+ cells from H60-vaccinated 
donors, which contained 3,500 TetH60+ 
cells. (A) Post-transplantation survival. (B) 
Representative TetH60 staining of blood CD8 
cells from WT and Ifngr–/– H60+ mBC-CML 
recipients and their quantitation (C) on day 
14 after transplantation. The percentage 
of blood NGFR+EGFP+ cells on day 14 after 
transplantation and the percentage of 
these cells that were MHCII+ are shown in 
D and E, respectively. For C–E, each symbol 
represents data from an individual mouse; 
horizontal lines represent the mean.  
P = 0.0034, comparing survival of recipients 
of WT H60+ BC-CML, with or without TMH60.  
P = 0.378, comparing survival of recipients 
of Ifngr–/– H60+ mBC-CM with or without 
TMH60. (F–H) Irradiated B6 mice were recon-
stituted with C3H.SW BM, WT or Ifngr–/– 
MLL-AF9 AML with no T cells, or with C3H.
SW CD4 or CD8 cells. Spleen and BM cells 
were harvested on day 13 after transplanta-
tion and analyzed for MLL-AF9 AML (GFP+) 
MHCII expression (F). Survival for CD4-me-
diated and CD8-mediated GVL is shown in 
G and H, respectively. P ≤ 0.0016, comparing 
the survival in the WT mAML BM-alone 
group with WT CD4 or CD8 recipients;  
P = 0.024, comparing Ifngr–/– BM alone with 
CD4 recipients; P = 0.0079 and P = 0.0053, 
comparing CD4 and CD8 recipients of WT 
versus Ifngr–/– MLL-AF9 AML, respectively.  
P values determined by 2-tailed Mann- 
Whitney U test. Data in G and H were  
combined from 2 repetitions.
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the effects of IFN-γ on mBC-CML cells 
in vitro. Culture in media plus IFN-γ, 
but not media alone, induced MHCII 
upregulation. With continuous culture 
in IFN-γ at concentrations detected in 
the serum of GVHD mice (31), MHCII 
upregulation was not detected until 24 
to 48 hours and usually peaked between 
48 and 72 hours (Figure 4A and data not 
shown). An IFN-γ pulse of as short as 1 
hour induced MHCII upregulation on a 
minority of cells at 72 hours, but max-
imum MHCII upregulation required 
exposure for 8 to 18 hours (Figure 4B). 
Despite this requirement, in vitro IFN-γ 
stimulation induced mBC-CML STAT1 
phosphorylation within 15 minutes 
(Figure 4C), indicating that, despite 
rapid STAT1 phosphorylation, more 
prolonged IFN-γR signaling is required 
for maximal MHCII upregulation. To 
determine whether the in vitro time 
course of MHCII upregulation paral-
lels what occurs in vivo, we transferred 
B6 MHCIIlo mBC-CML cells harvested 
from sublethally irradiated syngeneic 
B6 mice into irradiated B6 mice that 
were transplanted with C3H.SW BM, 
with or without C3H.SW CD4 cells, 7 
days earlier. We observed that MHCI 
and MHCII expression increased 
on splenic (Figure 4D) and BM (not 
shown) mBC-CML LSCs in GVH mice 
at 48 and 96 hours after transfer, but not in mice that did not 
receive CD4 cells.
These results identify a key mechanism that at least in part 
explains the resistance of mBC-CML and AML GVL against GVL 
compared with the GVL that develops against CP-CML. Effective 
GVL against mBC-CML and mAML requires sufficient and sus-
tained IFN-γ to sensitize LSCs to T cell killing, whereas effective 
GVL against mCP-CML does not require IFN-γ stimulation . mBC-
CML LSCs recovered from mice that were dying from leukemia 
at later times after transplantation, despite being transplanted 
with donor T cells, were mostly MHCIIlo. This decline in MHCII 
expression was not due to selection for cells that could not respond 
to IFN-γ, as MHCIIlo cells harvested from mice with progressive 
mBC-CML, despite receiving donor T cells, uniformly upregulated 
MHCII in vitro with IFN-γ stimulation (Figure 4E). This suggests 
that leukemia progression at later points after transplantation is 
due to both a contraction of the alloreactive T cell response and a 
drop in IFN-γ levels.
mBC-CML and mCP-CML gene expression changes in the GVH 
environment. To better understand potential mechanisms of action 
of IFN-γ, we performed gene expression analyses on WT and 
Ifngr–/– mBC-CML and WT mCP-CML LSCs sorted from mice 
that were or were not undergoing a GVH response. For mBC-CML 
LSCs, irradiated B6 mice were reconstituted with WT or Ifngr–/– 
expansion of H60-reactive T cells in blood that was at least as 
strong as that observed in recipients of WT B6.H60 mBC-CML 
(Figure 3, B and C). Whereas TMH60 reduced blood WT B6.H60 
mBC-CML cells, they failed to do the same against Ifngr–/– B6.H60 
mBC-CML (Figure 3D). Finally, H60-reactive CD8 cells induced 
MHCII upregulation (a marker for IFN-γ stimulation) only on WT 
B6.H60 mBC-CML cells (Figure 3E).
To determine whether the reliance on IFN-γ stimulation for 
effective GVL is unique to mBC-CML or is a more general property 
of myeloblastic leukemias, we created WT and Ifngr–/– AML by trans-
ducing WT or Ifngr–/– BM with a retrovirus encoding the MLL-AF9 
translocation (27) and then tested the sensitivities of these AML cells 
to CD4- and CD8-mediated GVL in the C3H.SWgB6 model. Cohorts 
were sacrificed 12 days after BMT for analysis of MHC expression 
on splenic and BM AML cells. CD4 and CD8 cells induced a modest 
upregulation of MHCII on WT AML cells but not on Ifngr–/– AML cells 
(Figure 3F). MHCI was not upregulated (date not shown). Important-
ly, compared with WT MLL-AF9, we found that Ifngr–/– MLL-AF9 
mAML was relatively resistant to both CD4- and CD8-mediated GVL 
(Figure 3, G and H).
IFN-γ is sufficient to upregulate MHC on mBC-CML cells. While 
the IFN-γR was required for MHC upregulation on mBC-CML cells 
in vivo, it was possible that other unidentified stimuli were also 
required. To test whether IFN-γ alone is sufficient, we examined 
Figure 4. In vitro IFN-γ treatment is sufficient to upregulate MHCII on mBC-CML LSCs. (A) Sort-purified 
mBC-CML LSCs were continuously cultured with graded concentrations of IFN-γ, and MHCII expression was 
measured 72 hours later. (B) mBC-CML LSCs were cultured for 30 minutes to 24 hours in IFN-γ (200 pg/ml). 
Stimulated cells were washed extensively and then further cultured without IFN-γ for a total culture time 
of 72 hours, followed by measurement of MHCII expression. The final supernatant from each wash was 
cultured with fresh mBC-CML cells for 72 hours, and MHCII was not upregulated (see “24-Hour wash super-
natant” in B). Data are representative of 2 experiments, with 3 replicates per condition. (C) mBC-CML cells 
were cultured in IFN-γ, and p-STAT1 was measured by flow cytometry at the indicated times. (D) Irradiated 
B6 mice were reconstituted with C3H.SW BM with or without C3H.SW CD4 cells. On day 7 after alloBMT, 
sort-purified mBC-CML LSCs were injected. mBC-CML cells were recovered 48 and 96 hours later and MHCI 
and MHCII expression was analyzed by flow cytometry. Shown are data from splenic mBC-CML cells; data 
in BM were similar (not shown). Each line represents data from an individual mouse. (E) Irradiated B6 
mice were transplanted with mBC-CML cells, C3H.SW BM, and CD4 cells. On day 21 after transplantation, 
sort-purified splenic MHCII– CD11b– mBC-CML cells were cultured with or without IFN-γ for 72 hours. IFN-γ 
induced MHCII expression.
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Figure 5. Gene expression analyses of mBC-CML and mCP-CML LSCs. (A–D) 
WT or Ifngr–/– mBC-CML cells were harvested from C3H.SW→B6 recipients 
of C3H.SW CD4 cells. Shown are Gene Set Enrichment Analysis–style (GSEA-
style) barcode plots for IFN-γ pathway gene expression using hallmark data. 
Note the significant upregulation of IFN-γR pathway genes comparing WT 
mBC-CML cells harvested from CD4 recipients with WT mBC-CML LSCs from 
BM-alone recipients (A), Ifngr–/– mBC-CML LSCs from CD4 recipients (B), and 
Ifngr–/– mBC-CML LSCs from BM-alone recipients (C). There was no IFN-γR 
signature comparing Ifngr–/– mBC-CML LSCs harvested from CD4 recipients 
compared with those from BM-alone recipients (D), and few differentially 
expressed genes distinguished these groups (Supplemental Figure 1). (E) 
WT B6 mCP-CML LSCs were harvested from BALB/c recipients that did or 
did not receive CD4 cells (BM alone). An IFN-γR signature was observed in 
RNA from LSCs harvested from CD4 recipients as compared to RNA from 
LSCs from BM alone controls.
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mBC-CML cells, C3H.SW T cell–depleted BM, with or without 
C3H.SW CD4 cells. For mCP-CML, to facilitate recovery of suf-
ficient mCP-CML cells, we again used the B6gBALB/c GVH sys-
tem with B6 mCP-CML cells, with or without B6 CD4 cells. mBC-
CML and LSK mCP-CML cells (lin–) were harvested between days 
12 and 14 after BMT. LSCs from 3 individual mice were analyzed 
from each group.
We saw a clear IFN-γ gene signature when comparing mRNA 
from Ifngr–/– mBC-CML cells from the BM-alone group with mRNA 
from WT mBC-CML cells harvested from CD4 recipients (Figure 5). 
Relative to the Ifngr–/– groups, there was a background IFN-γ signa-
ture in WT mBC-CML cells harvested from the B6 BM-alone group, 
probably due to IFN-γ produced by the host-versus-graft response. 
In addition to a classic IFN-γ signature, in WT BC-CML cells from 
GVH mice, we observed changes in genes linked to antigen pre-
sentation, ubiquitination, proteasome function, and apoptosis. As 
expected, there was no IFN-γ signature in the IFN-γR mBC-CML 
cells. By volcano plot analysis, we found that gene expression was 
similar in Ifngr–/– mBC-CML LSCs harvested from the BM-alone 
and CD4 groups, and pathway analyses were unrevealing as to what 
drove the few observed differences (data not shown).
mCP-CML gene expression analysis. We also detected an IFN-γ 
signature in mCP-CML LSCs harvested from CD4 recipients relative 
to LSCs harvested from mice treated with BM alone (Supplemental 
Figure 1; supplemental material available online with this article; 
https://doi.org/10.1172/JCI85736DS1). Therefore, the fact that WT 
mCP-CML and Ifngr–/– mCP-CML were equivalently GVL sensitive 
was not due to WT mCP-CML being unresponsive to IFN-γ.
T cells are the critical source of IFN-γ. T cells are the major, but 
not exclusive, producers of IFN-γ. To determine whether donor 
T cell–derived IFN-γ is required for MHC upregulation and GVL, 
we compared mBC-CML MHC upregulation and GVL in recipi-
ents of WT or IFN-γ–deficient CD4+ T cells. Because TCR-MHC 
interactions were not required for MHC upregulation, we also 
considered the possibility that T cells unable to directly kill leu-
kemia cells could provide IFN-γ in trans, thereby rescuing the 
inability of IFN-γ–deficient T cells to mediate GVL. Irradiated 
B6 mice were reconstituted with B6 B2m–/– mBC-CML (MHCI–) 
and BALB/c BM with: a) no T cells; b) WT or IFN-γ–deficient 
BALB/c CD4 cells; or c) WT or IFN-γ–deficient CD4 cells with 
WT or IFN-γ–deficient BALB/c CD8 cells. B2m–/– mBC-CML was 
used to prevent donor CD8 cells from directly killing leukemia 
cells. Whereas WT CD4 cells induced MHCII expression and 
reduced the number of splenic and BM mBC-CML cells by day 
14 after BMT, IFN-γ–deficient CD4 cells failed to do so (Figure 6, 
A–C, and data not shown), indicating that donor T cell–derived 
IFN-γ is critical. The addition of WT, but not IFN-γ–deficient, 
CD8 cells restored IFN-γ–induced MHCII upregulation and 
diminished the number of mBC-CML cells in spleen and BM 
by day 14 (Figure 6, A–C, and not shown), indicative of a GVL- 
promoting effect. Consistent with this early GVL effect, the addi-
tion of WT, but not IFN-γ–deficient, CD8 cells to IFN-γ–deficient 
CD4 cells prolonged the survival of mice in 2 of 3 repeated exper-
iments (Figure 6D). The rescue of IFN-γ–deficient CD4 cells by 
WT CD8 cells may have been incomplete because of differences 
in the kinetics and magnitude of IFN-γ production by CD4 and 
CD8 cells, which is consistent with the lower mean fluorescence 
intensity (MFI) of MHCII in the IFN-γ–deficient CD4 plus WT 
CD8 group (mean of 443 vs. 167). That the addition of WT CD8 
cells to IFN-γ–deficient CD4 cells restored GVL also confirms 
that the inability of IFN-γ–deficient CD4 cells to mediate GVL 
was not due to a failure to generate cytolytic effectors.
IFN-γ alone is insufficient for GVL. Given the complete GVL 
resistance of Ifngr–/– mBC-CML, we considered the possibility that 
IFN-γ alone has direct and meaningful antileukemia activity. Argu-
ing against this is that for effective GVL, CD4 and CD8 cells require 
leukemia expression of MHCII and MHCI, respectively (10, 11, 24) 
despite alloreactive T cells activated in response to recipient allo-
antigens generating substantial IFN-γ. However, sufficiently high 
local IFN-γ levels may only be achieved when IFN-γ–producing T 
cells make cognate TCR-MHC contacts. To test this hypothesis, 
we engineered a situation in which cognate TCR-MHC interac-
tions occurred, but perforin and death receptor–dependent T cell–
induced apoptosis and necroptosis were prevented. We first creat-
ed Fas (TNFRSF6) via Fas-associated protein with death domain 
(Fadd–/– Ripk3–/–) mBC-CML cells. FADD is required for all death 
receptor signaling; however, Fadd–/– mice are embryonically lethal 
unless they are crossed with Ripk3–/– mice due to the role of FADD 
in inhibiting RIPK3-dependent necroptosis (32). We then compared 
GVL mediated by WT or perforin–/– CD4 or CD8 cells against Fadd–/– 
Ripk3–/– and control Fadd+/– Ripk3+/– mBC-CML. Effective GVL only 
required either WT T cells or FADD/RIPK3-intact mBC-CML (Fig-
ure 7). In contrast, GVL was completely abrogated when donor T 
cells were perforin–/– and mBC-CML cells were Fadd–/– Ripk3–/–, 
despite T cells being capable of producing IFN-γ and making TCR-
MHC contacts with mBC-CML cells. Therefore, CD4- and CD8- 
dependent GVL depends on T cell perforin and/or mBC-CML death 
receptor signaling, and T cell–derived IFN-γ alone is insufficient.
Discussion
Relapsed acute leukemia after alloSCT remains a major unmet medi-
cal need. Much of the early and exciting efficacy of alloSCT as a form 
of adoptive T cell immunotherapy was observed in patients with 
CP-CML (33); however, in the tyrosine kinase inhibitor era, these 
patients infrequently undergo transplantation. While GVL is active 
against myeloblastic leukemias, it is less potent than GVL against 
CP-CML. This difference in potency is reflected in the higher rates 
of BC-CML and AML relapse after alloSCT. Unfortunately, there has 
been little progress in decreasing or treating relapses, in which the 
withdrawal of immunosuppression and donor leukocyte infusions 
infrequently result in durable remissions. A major barrier to prog-
ress has been a lack of understanding of the resistance mechanisms. 
A central paradox, evident since the early days of clinical alloSCT, 
is why an alloimmune response sufficient to cause GVHD, promote 
100% donor hematopoietic chimerism, and mediate GVL against 
CP-CML is so much less effective against AML. Here, we report a 
mechanism that may explain this: the alloimmune T cell response 
against AML and BC-CML must generate sufficient IFN-γ to sensi-
tize myeloblast LSCs to T cell killing. In contrast, a smaller and more 
smoldering alloreactive response, which does not generate high lev-
els of IFN-γ, is sufficient for GVL against mCP-CML and for GVHD.
Ifngr–/– mBC-CML and MLL-AF9 mAML were GVL resis-
tant, and, conversely, IFN-γ–deficient T cells mediated no 
GVL against mBC-CML, despite their expansion and induction 
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STAT2, even though gene expression analysis indicated that 
mCP-CML LSCs are IFN-γ responsive.
In an effort to understand the cell-intrinsic properties of mBC-
CML cells that render them GVL resistant relative to CP-CML cells, 
we have tested in GVL models mouse blast crisis and chronic phase 
leukemias deficient in numerous genes including those encoding 
β2M, MHCII, Fas, TRAIL, TNFR1/R2, PD-L1, PD-L2, ICAM-1, and 
IFNAR1 (10, 11, 24, 25). Until the present study, we found no defi-
ciency that selectively diminished GVL against mBC-CML without 
equivalently reducing GVL against mCP-CML.
Other factors in addition to the requirement for IFN-γR signal-
ing may also contribute to the relative GVL resistance of myeloblas-
tic leukemias as compared with that of CP-CML. Nonetheless, the 
of clinical GVHD (data not shown). In mouse models without 
immunosuppression, there is an early wave of IFN-γ produc-
tion coincident with rapid alloreactive T cell expansion (34–36). 
However, in clinical alloSCT, in which pharmacologic immuno-
suppression is given, such a rise in IFN-γ may only infrequently 
occur, and this may in part contribute to the more global GVL 
resistance of myeloblastic leukemias. Chronic GVHD (cGVHD) 
has been associated with a lower risk for AML relapse, and 
recent data suggest that cGVHD is associated with the action of 
IFN-γ (37). Perhaps the sustained IFN-γ associated with cGVHD 
contributes to GVL, along with alloreactive cytolytic T cells. In 
contrast, GVL against mCP-CML was independent of type I and 
II IFNs or their downstream signaling components STAT1 and 
Figure 6. T cell–derived IFN-γ delivered in cis or in trans is required for CD4-mediated GVL. Irradiated B6 mice were reconstituted with BALB/c BM and B6 
B2m–/– mBC-CML with no T cells or with the following BALB/c background T cells: (i) WT CD4 cells; (ii) IFN-γ–deficient CD4 cells; (iii) WT CD4 cells plus WT CD8 
cells; (iv) IFN-γ–deficient CD4 cells plus WT CD8 cells; or (v) IFN-γ–deficient CD4 cells plus IFN-γ–deficient CD8 cells. Cohorts were sacrificed 10–14 days after 
transplantation, and mBC-CML cells were analyzed by flow cytometry. (A) Representative flow cytometry from splenocytes. (B) Percentage of leukemic sple-
nocytes from individual mice (n = 3 independent experiments). Each symbol represents data from an individual mouse; horizontal lines indicate mean values. 
(C) Upper panel: WT, but not IFN-γ–deficient, CD4 or CD8 cells induced MHCII upregulation on mBC-CML LSCs. The upper panel shows LSC MHCII expression. 
Each line represents data from an individual mouse.  Lower panel: Percentage of LSCs that were MHCII+ from 2 of 3 experiments. Each symbol represents 
data from an individual mouse; horizontal lines indicate the mean values. Insufficient numbers of LSCs were present to analyze in the third experiment (see 
bottom panel in Figure 5B). (D) In 2 of 3 experiments, the addition of WT CD8 cells, but not IFN-γ–deficient CD8 cells, to IFN-γ–deficient CD4 cells prolonged 
survival (data were combined from 2 experiments). P = 0.0037 comparing the KO CD4 + WT CD8 group to either the KO CD4 or KO CD4 + KO CD8 groups.
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of T cells that recognize allogeneic MHC (46, 47) 
and the diminished likelihood that GVL in this 
model would rely on a single targeted peptide. 
IFN-γ upregulates ICAM-1 (data not shown), 
immunoproteasome components, and chemo-
kines that attract T cells and modifies pro- and 
antiapoptotic pathways (Figure 5 and ref. 48), all 
of which could promote effective CD8 cell kill-
ing. Discovering precisely how IFN-γR signaling 
sensitizes mBC-CML and AML cells to killing 
will require substantial further investigation, and 
given the pleiotropic effects of IFN-γR signaling, 
it is possible that no single downstream mech-
anism will explain its dominant role. Another 
intriguing and unanswered question is what sig-
nal(s) in the alloimmune environment induce 
MHCII upregulation on mCP-CML LSCs. Given 
that TCR-MHC interactions are also not required, 
a soluble factor is most likely responsible.
We used Fadd–/– Ripk3–/– mBC-CML and 
perforin–/– T cells to demonstrate that, despite 
IFN-γ being critical for GVL, alone it is insuffi-
cient, as there was no GVL when T cells lacked 
perforin and leukemias lacked FADD and 
RIPK3. These data also highlight the idea that 
cytolytic pathways engaged by both CD4 and 
CD8 cells are redundant, in that either perforin or death receptor 
FADD/RIPK3-dependent killing is sufficient for GVL.
We studied models of CP-CML, BC-CML, and AML, which 
share essential genetic and phenotypic features with their 
human counterparts (49). It will be important to determine 
the importance of IFN-γ in GVL against other mouse myeloid 
leukemias and against human AML samples. Available data 
suggest that IFN-γ could broadly impact GVL against human 
AML. Human AML stem cells include MHCII– cells (50), and 
acute promyelocytic AML is classically MHCII–. Other leuke-
mias reported to be MHCII+ usually have cell populations that 
are MHCII–, as the MHCII expression threshold for calling an 
AML MHCII+ does not require all cells to express MHCII (51–
54). Therefore, if alloreactive CD4 cells are to directly medi-
ate GVL against these MHCII– cells, MHCII expression must 
be induced. Primary human AML cells and AML-like cell lines 
express the IFN-γR and are IFN-γ responsive (48, 55–62), with 
both basal and IFN-γ–induced STAT1 phosphorylation (58) and 
MHCI and MHCII upregulation. We hope our results demon-
strating a critical role for IFN-γ in GVL responses against two 
clinically relevant mouse models of myeloblastic leukemias 
will both stimulate a broader evaluation of the IFN-γ respon-
siveness  of additional mouse AML models and of human AML 
specimens classified by molecular features, and the develop-
ment of approaches to safely deliver IFN-γ in the clinic.
Methods
Mice
C57BL6 (B6; H-2b) and BALB/c (H-2d) mice were purchased from 
Harlan Laboratories. C3H.SW mice were purchased from The Jack-
present results argue that GVL could be meaningfully augmented 
by exposing malignant myeloblasts to IFN-γ after transplantation, 
timed to coincide with the presence of alloreactive cytolytic T cells. 
The key translational question is how to achieve this. IFN-γ–induced 
MHC upregulation and GVL sensitization do not require TCR-MHC 
contacts between IFN-γ–producing T cells and leukemia cells (see 
Figures 1 and 5). That is, IFN-γ can be delivered to leukemia cells in 
trans by T cells that do not target the leukemia cells. This suggests 
a feasible clinical strategy. CMV reactivation early after transplanta-
tion and the use of CMV seropositive donors have been associated 
with lower rates of AML relapse (38–41). CMV reactivation induces 
the expansion of CMV-reactive T cells and NKG2C+ NK cells (42), 
both of which can produce IFN-γ and raise serum IFN-γ levels (43). 
Although other explanations are possible, our data suggest that 
anti-CMV immune responses could be promoting GVL through the 
elaboration of IFN-γ. Approaches to further promote the anti-CMV 
immune response, perhaps by donor and recipient anti-CMV vacci-
nation (44, 45), might augment GVL without an increase in GVHD. 
This strategy is analogous to our use of IFN-γ–positive CD8 cells to 
promote GVL by IFN-γ–deficient CD4 cells.
That IFN-γ was required for CD4-mediated GVL is easy to 
understand, given its importance in upregulating MHCII. How-
ever, it was surprising that Ifngr–/– mBC-CML and MLL-AF9 
mAML were resistant to CD8-mediated GVL, as these leukemias 
are MHCI+ at baseline, and IFN-γ–induced MHCI upregulation is 
modest or does not occur in the case of MLL-AF9 AML. It is pos-
sible that MHCI upregulation crosses a threshold of MHCI-miHA 
peptide complexes to sufficiently engage alloreactive T cells. How-
ever, the fact that Ifngr–/– mBC-CML was also resistant to CD8- 
mediated GVL in the MHC-mismatched setting argues against this 
being the sole explanation, considering the much higher frequency 
Figure 7. CD4 and CD8-mediated GVL require intact T cell perforin or leukemia FADD/RIPK3, 
and T cell–derived IFN-γ alone is insufficient for GVL. Irradiated B6 mice were reconstituted with 
BALB/c BM and B6 Fadd–/– Ripk3–/– (DKO) or control B6 Fadd+/– Ripk3+/– mBC-CML (WT) with no 
BALB/c T cells or with WT or perforin–/– CD8 cells (A) or CD4 cells (B). Data show survival rates from 
1 of 2 similar experiments with 10 mice per group. P < 0.0003, comparing any WT or DKO BM-alone 
group with any WT T cell group. P > 0.07, comparing DKO BM-alone versus perforin–/– CD4 or CD8 
groups. P values determined by 2-tailed Mann-Whitney U test.
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TIB120; lab-prepared); CD117 phycoerythrin (PE) and Sca-1 FITC 
(BD Pharmingen; clones 2B8 and Ly-6a/E); and anti-NGFR Alexa 647 
(clone HB8737; lab-prepared). mBC-CML cells (lin–) could be identi-
fied by only staining for CD11b. Staining for Kb and I-A/I-E (MHCII) 
was done with clones AF6-88.5 and M5/114.15.2, respectively (BioLeg-
end). Phosphorylated STAT1 (p-STAT1) staining was performed with 
or without IFN-γ stimulation, followed by fixation in 2% paraformalde-
hyde in PBS. The cells were permeabilized in BD Phosflow Perm Buffer 
III for 30 minutes on ice, washed twice in BD Pharmingen Stain Buf-
fer, and stained with PE-conjugated p-STAT1 antibody (pY701; BD). 
H60-reactive T cells, which detect the LTFNYRNL peptide bound to 
Kb, were identified by MHCI tetramer staining (TetH60+). H60 tetram-
ers were created at the NIH’s tetramer facility (Atlanta, Georgia, USA).
Cell purifications
Lymph node (LN) and splenic cells were prepared as previously 
described (11). T cell purifications were performed using EasySep neg-
ative selection reagents according to the manufacturer’s instructions 
(STEMCELL Technologies). Cell purities were greater than 88%, 
with less than 2% of contaminating CD4 or CD8 cells. CD8 memory 
T cells were isolated from H60-vaccinated mice by first using a CD8 
EasySep negative selection kit. Cells were then stained with antibod-
ies against CD8 and CD44, followed by sorting on a FACSAria cell 
sorter (BD Biosciences).
In vitro mBC-CML stimulation
Splenocytes from sublethally irradiated B6 mice injected with mBC-
CML cells approximately 2 to 3 weeks earlier (at least 80% EGFP+ 
NGFR+) were cultured for different lengths of time in DMEM with 
10% FCS with graded amounts of IFN-γ (Peprotech). In experiments 
in which IFN-γ was removed and cells were recultured, cells were 
washed 4 times in 50 cc of media. The final supernatant was cultured 
with fresh mBC-CML cells for another 72 hours as a confirmation that 
IFN-γ had been removed. At the end of the culture period, cells were 
more than 80% viable.
Gene expression profiling
mCP-CML. Irradiated BALB/c mice were reconstituted with B6 BM, 
7 × 105 BCR-ABL spin-infected B6 BM (see leukemia induction) with 
no B6 T cells, or with 5 × 105 B6 CD4 cells. On day 12 after BMT, 
NGFR+ LSK cells were separately sorted from the spleens of 3 individ-
ual mice from each group.
mBC-CML. Irradiated B6 mice were reconstituted with C3H.
SW BM, B6 WT or Ifngr–/– mBC-CML, with no T cells, or with 4 × 106 
C3H.SW CD4 cells. On day 14 after BMT, lin– mBC-CML cells were 
sorted from the spleens of 3 individual mice from each group. RNA 
was isolated using a QIAGEN RNA Extraction Kit, followed by library 
preparation using an Epicentre kit. Expression was analyzed by quan-
titation using an Illumina WG-6 v2.0 Expression BeadChip. Differen-
tial expression was computed using the Bioconductor package (67), 
and pathway analysis was performed using the limma “camera” func-
tion (68), which controls for intercorrelation among genes, and the 
“canonical pathways” gene sets provided by mSigDB (69).
Statistics
Survival differences were calculated using the log-rank test (Mantel- 
Cox) (GraphPad Prism; GraphPad Software version 7). In some 
son Laboratory and bred at Yale University. IFN-γ–deficient (63) and 
perforin–/– mice backcrossed with BALB/c mice (64, 65) were bred at 
the University of Iowa and at Yale University. Ifngr–/– mice were pur-
chased from the Jackson Laboratory. Ifnar1–/– mice were obtained 
from H. Rosenberg (66) (National Cancer Institute [NCI], Bethesda, 
Maryland, USA) and bred at Yale University. Ifnar1–/– Ifngr–/– mice were 
obtained from William Klimstra (University of Pittsburgh School of 
Medicine, Pittsburgh, Pennsylvania, USA). Stat1–/– Stat2–/– mice were 
obtained from John Alcorn (University of Pittsburgh). B6.H60 mice 
were originally obtained from Derry Roopenian (The Jackson Labora-
tory) and were bred at the University of Pittsburgh. B6 Fadd–/– Ripk3–/– 
and control B6 Fadd–/+ Ripk3–/+ mice were maintained at St. Jude Chil-
dren’s Research Hospital (Memphis, Tennessee, USA) (32).
Leukemia induction
mBC-CML and mCP-CML were created as previously described 
(11, 12). Briefly, mBC-CML was created by spin-infection of BM 
from 5FU-treated mice with two MSCV2.2-based retroviruses, one 
expressing BCR-ABL (along with a truncated and nonsignaling 
human nerve growth factor receptor [NGFR]) and a second express-
ing NUP98 and HOXA9 (coexpressing GFP) (11). MLL-AF9 AML 
was induced by transduction with an MSCV2.2-based retrovirus 
encoding the MLL-AF9 fusion cDNA and GFP (27) (gift of Scott Arm-
strong, Memorial Sloan Kettering Institute, New York, New York, 
USA). Cells were passaged in vivo and frozen. For each experiment 
mCP-CML was created by spin-infection with BCR-ABL retrovirus 
alone as described previously (24).
BMT
Four different strain pairings were used in alloBMT experiments. All 
irradiation was delivered by a cesium irradiator. All BM was T cell 
depleted and is referred to herein as BM.
C3H.SW (H-2b)→B6 (H-2b). B6 mice received 900 cGy irradiation 
and were reconstituted with 5 × 106 to 7 × 106 C3H.SW BM, with or 
without bead-purified C3H.SW CD4 or CD8 cells.
C3H.SW→B6.H60. B6.H60 mice received 900cGy irradiation 
and were reconstituted with 7 × 106 C3H.SW BM cells and CD8+CD44+ 
cells from C3H.SW mice vaccinated against H60 as previously 
described (26).
BALB/c (H-2d)→B6. B6 mice were irradiated (900 cGy) and 
reconstituted with 107 BALB/c BM cells, with or without purified 
BALB/c (WT or gene-deficient) CD4 or CD8 cells.
B6→BALB/c. Irradiated BALB/c mice (900 cGy) were reconsti-
tuted with 107 B6 BM cells, with or without purified B6 CD4 or CD8 
cells. mBC-CML and AML cells were either from frozen stocks or 
fresh cells harvested from sublethally irradiated B6 mice seeded 14 to 
21 days beforehand. Two hundred micrograms anti-NK1.1 (PKC136; 
lab-prepared) was given i.p. on days –2 and –1 in experiments with the 
BALB/c→B6 strain pair and on days –2, –1, and +7 in experiments with 
β2M–/– mBC-CML to prevent NK cell–mediated killing of MHCI– or 
H-2d+b– cells.
Antibodies and flow cytometry
mCP-CML LSCs were identified by excluding lin+ cells using stain-
ing with biotin-conjugated antibodies against TER-119, Gr-1, CD19, 
and CD11b (all from BD Pharmingen; clones TER-119, RB6-8C5, 
1D3, and M1/70, respectively); CD4 and CD8 (clones GK1.5 and 
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